Vaccine for prevention of toxoplasma infection as well as preparation method and application of vaccine

Abstract

The invention provides a nucleotide sequence for prevention of toxoplasma infection. The nucleotide sequence for prevention of toxoplasma infection contains nucleotide sequences selected from (1) a nucleotide sequence as shown in SEQ ID No.1 of a sequence table, (2) a nucleotide sequence complementary with the nucleotide sequence as shown in the (1), and (3) a nucleotide sequence obtained by replacing, deleting, adding and modifying one or multiple of basic groups of the nucleotide sequence as shown in the (1) or (2) and having a function of preventing toxoplasma infection. The invention also provides a vaccine which comprises the nucleotide sequence and a medically acceptable carrier. The plasmid DNA vaccine pVAX-ROP38 can be used for effectively preventing and controlling infection of toxoplasma animal models (Kunming strain mouse), namely can be used for effectively prolonging the survival time of the mouse and reducing the worm burden of brain capsules. Therefore, the plasmid pVAX-ROP38 can serve as a DNA vaccine candidate antigen for resisting toxoplasma infection.

Description

technical field [0001] The invention belongs to the fields of immunology and molecular biology, and in particular relates to a vaccine for preventing toxoplasma gondii infection. Background technique [0002] Toxoplasma gondii (T.gondii) is an obligate intracellular parasitic protozoan that can cause zoonotic toxoplasmosis. Toxoplasma gondii can infect almost all mammals including humans, and cats are the main source of infection. About 1 / 3 of the adults in the world are infected, the infection rate of the Chinese population is 5% to 20%, and the infection rate of livestock animals is 10% to 50%. As an opportunistic pathogenic factor, Toxoplasma gondii is usually recessively infected in normal hosts without obvious clinical symptoms; but for organ transplantation, AIDS, malignant tumor patients and other immunodeficiency or immunosuppression patients, Toxoplasma gondii may be fatal. One of the factors; Toxoplasma gondii infection in pregnant women can lead to miscarriage, ...

AI Technical Summary

Problems solved by technology

The safety of inactivated vaccine is better, but its anti-infection ability is weak; the attenuated vaccine has better protection, but in terms of safety, there has always been a strong virulence and the formation of tissue packets in the body after Toxoplasma infection of the intermediate host. The production process of genetically engineered vaccines is complicated, the technology is difficult, and the production cost is high, and its protection and safety need to be further improved; nucleic acid vaccines do not need to use adjuvants, do not need to express and purify recombinant antigens, and can produce The role of CTL, the persistence of immunity, and the ability to make multivalent vaccines have been widely used.

Images